VivaVision Biotech, Inc

Quick facts

Phase 3 pipeline

• VVN001 Ophthalmic Solution, 5% · Ophthalmology
  VVN001 Ophthalmic Solution, 5% is a corticosteroid that reduces inflammation in the eye.
• VVN001 Ophthalmic Solution, Vehicle · Ophthalmology
  VVN001 Ophthalmic Solution, Vehicle is a topical ophthalmic solution used to facilitate the administration of other eye medications.
• VVN461 Ophthalmic Solution 1.0% · Ophthalmology
  VVN461 is an ophthalmic solution designed to treat ocular surface disease by modulating inflammatory pathways in the eye.

Phase 2 pipeline

• VVN001 Ophthalmic Solution 1%
• VVN461 Ophthalmic Solution 0.5%
• VVN539 Ophthalmic Solution 0.02%
• VVN539 Ophthalmic Solution 0.04%

Phase 1 pipeline

• VVN461 Ophthalmic Solution 0.25%

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• VivaVision Biotech, Inc portfolio CI brief
• VivaVision Biotech, Inc pipeline updates RSS